AstraZeneca plc (LON:AZN) had its price target cut by Jefferies Group LLC from GBX 4,900 ($63.61) to GBX 4,400 ($57.12) in a research report released on Tuesday, August 1st. They currently have a hold rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on the company. Barclays PLC reaffirmed an overweight rating and set a GBX 5,500 ($71.40) target price on shares of AstraZeneca plc in a report on Tuesday, August 1st. Morgan Stanley downgraded AstraZeneca plc to an equal weight rating and reduced their target price for the stock from GBX 5,600 ($72.70) to GBX 4,700 ($61.02) in a report on Friday, July 28th. Beaufort Securities downgraded AstraZeneca plc to a sell rating and set a GBX 3,900 ($50.63) target price on the stock. in a report on Friday, July 28th. J P Morgan Chase & Co reaffirmed a neutral rating and set a GBX 4,200 ($54.52) target price (down previously from GBX 5,000 ($64.91)) on shares of AstraZeneca plc in a report on Friday, July 28th. Finally, Kepler Capital Markets set a GBX 5,200 ($67.51) target price on AstraZeneca plc and gave the stock a buy rating in a report on Friday, July 28th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of GBX 4,932.67 ($64.04).
Shares of AstraZeneca plc (LON AZN) opened at 4447.00 on Tuesday. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The stock’s market cap is GBX 56.30 billion. The firm has a 50-day moving average price of GBX 4,818.59 and a 200-day moving average price of GBX 4,862.48.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/jefferies-group-llc-lowers-astrazeneca-plc-lonazn-price-target-to-gbx-4400-updated-updated.html.
The firm also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be paid a GBX 68.90 ($0.89) dividend. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.
In other news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.